Abstract
Advances in the sophisticated instruments for the isolation and characterization of marine natural products, and development in the biological assay systems, have resulted in the discovery of various compounds of biomedical application. Marine natural products have been a source of new leads for the treatment of many deadly diseases such as cancer, acquired immuno-deficiency syndrome (AIDS) etc. The compounds of marine origin are diverse in structural class from simple linear peptides to complex macrocyclic polyethers. Number of marine peptides have been isolated in recent years which exhibit potent biological activities, and many of the compounds showed promising anticancer activity. Didemnin was the first marine peptide that entered in human clinical trials in US for the treatment of cancer, and other anticancer peptides such as kahalalide F, hemiasterlin, dolastatins, cemadotin, soblidotin, didemnins and aplidine have entered in the clinical trials. Clinical status of anticancer marine derived pep tides have been discussed and reviewed.
Keywords: Kahalalide F, Hemiasterlin, Dolastatins, Cemadotin, Soblidotin, Didemnins, Aplidine
Anti-Cancer Agents in Medicinal Chemistry
Title: Marine Peptides and Related Compounds in Clinical Trial+
Volume: 6 Issue: 1
Author(s): Diwan S. Rawat, Mukesh C. Joshi, Penny Joshi and Himanshu Atheaya
Affiliation:
Keywords: Kahalalide F, Hemiasterlin, Dolastatins, Cemadotin, Soblidotin, Didemnins, Aplidine
Abstract: Advances in the sophisticated instruments for the isolation and characterization of marine natural products, and development in the biological assay systems, have resulted in the discovery of various compounds of biomedical application. Marine natural products have been a source of new leads for the treatment of many deadly diseases such as cancer, acquired immuno-deficiency syndrome (AIDS) etc. The compounds of marine origin are diverse in structural class from simple linear peptides to complex macrocyclic polyethers. Number of marine peptides have been isolated in recent years which exhibit potent biological activities, and many of the compounds showed promising anticancer activity. Didemnin was the first marine peptide that entered in human clinical trials in US for the treatment of cancer, and other anticancer peptides such as kahalalide F, hemiasterlin, dolastatins, cemadotin, soblidotin, didemnins and aplidine have entered in the clinical trials. Clinical status of anticancer marine derived pep tides have been discussed and reviewed.
Export Options
About this article
Cite this article as:
Rawat S. Diwan, Joshi C. Mukesh, Joshi Penny and Atheaya Himanshu, Marine Peptides and Related Compounds in Clinical Trial+, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (1) . https://dx.doi.org/10.2174/187152006774755519
DOI https://dx.doi.org/10.2174/187152006774755519 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor
Current Cancer Drug Targets Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Current Pharmaceutical Design Formulation and Evaluation of Resveratrol Loaded Cubosomal Nanoformulation for Topical Delivery
Current Drug Delivery Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry NMR-based Drug Development and Improvement Against Malignant Melanoma – Implications for the MIA Protein Family
Current Medicinal Chemistry Therapeutic Potential of Medicinal Plant Proteins: Present Status and Future Perspectives
Current Protein & Peptide Science Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Molecular Mechanisms and Biological Significance of CTL Avidity
Current HIV Research Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism